Open Innovation in Drug Development: A Case Study of Company L and QPS

• Main Authors: Bhor, Kanchan Hanuman, 黎班杰
• Other Authors: Chang, Yuan-Chieh
• Format: Others
• Language: en_US
• Published: 2018
• Online Access: http://ndltd.ncl.edu.tw/handle/b7kk45

碩士 === 國立清華大學 === 國際專業管理碩士班 === 106 === Biotech and pharmaceutical companies are struggling for drug time line and cost cutting. For opening the door of innovation, companies need to come in relationship with other organizations to share with innovative idea and expertise. In this research work, I explore the concept of open innovation in pharmaceutical industry. Drug development goes through complex processes like drug discovery, clinical trials phases and post-marketing surveillance. For being these processes, they need to do huge investment in R & D projects. Thus, for reducing R & D cost along with product lifecycle, pharmaceutical and biotech companies need to develop an external network with different partners like contract research organizations (CROs) and universities by using both spin-in (outside in) and spin-off (inside out) open innovation. Here, I use an example of company L (pharma) and QPS (CRO) to demonstrate the processes and benefits of open innovation. Furthermore, pharma companies enter into a symbiotic relationship with biotech firms to exchange technologies and knowledge by exploring their innovation processes. This thesis also sheds light on how open innovation benefits to the pharma L and QPS.